Vitiligo of left upper eyelid and periocular area in India: Symptoms, Causes & Treatment | aihealz
ICD variantVitiligo of left upper eyelid and periocular area is a specific ICD-10 coded subtype of Vitiligo. The clinical content below covers Vitiligo in general.
OphthalmologymoderateICD-10 · H02.734
Vitiligo of left upper eyelid and periocular area.Care & specialists in India
In India, vitiligo of left upper eyelid and periocular area is managed by ophthalmologists. Vitiligo is a chronic autoimmune skin disease in which CD8+ T cells destroy epidermal melanocytes, producing the sharply defined milk-white patches that define the disorder. It affects roughly 0.5-2% of people worldwide, with prevalence around 0.5-1% in the United States and Europe and as high as 8.8% in some regions of India and Gujarat.
Vitiligo (ICD-10: L80) is an acquired autoimmune disease characterized by the selective destruction of epidermal melanocytes, the pigment-producing cells that synthesize melanin. CD8+ cytotoxic T cells, driven largely by the interferon-gamma and CXCL9/CXCL10 chemokine axis, recognize melanocyte antigens such as tyrosinase and target them for destruction, leaving sharply demarcated milk-white macules and patches without functional pigment. The condition is now classified, by the Vitiligo Global Issues Consensus Conference (Ezzedine 2012), into two principal forms: non-segmental vitiligo (NSV, including the generalized and acrofacial subtypes), which is bilateral, symmetric, and chronic with periods of activity; and segmental vitiligo (SV), which follows a unilateral, dermatomal-like distribution and typically stabilizes within 1-2 years. Mixed and unclassified variants exist.
key facts
Prevalence
0.5-2% globally; ~1% of US adults; up to 8.8% in some Indian regional surveys
Demographics
Affects men and women equally; reported across all ethnicities; psychosocial burden disproportionate in darker skin types
Avg. age
Half of cases begin before age 20; mean age of onset around 20-24 years
Global cases
~70-100 million people worldwide
Specialist
Ophthalmology
ICD-10
H02.734
§ 02
How you might notice it
The key symptoms of Vitiligo of left upper eyelid and periocular area are: Sharply demarcated, milk-white or chalk-white macules and patches with a clear border separating depigmented from normally pigmented skin — most often on the hands, face, around the mouth and eyes, elbows, knees, and over bony prominences., Symmetric distribution in non-segmental disease, with new patches commonly appearing at sites of friction, pressure, or skin injury — the Koebner phenomenon — typically 10-14 days after trauma in roughly 20-30% of patients., Premature greying or whitening of scalp hair, eyebrows, eyelashes, or beard (leukotrichia) within affected patches, indicating loss of follicular melanocytes and a poorer repigmentation prognosis at that site., Trichrome appearance at the edge of expanding patches, with a pale intermediate zone between fully depigmented centre and normally pigmented surrounding skin — a sign of active disease., Confetti-like depigmentation — small 1-5 mm white macules at the periphery of larger patches — a clinical marker of rapidly progressive vitiligo., Patches are typically asymptomatic, but a minority of patients report mild itching, burning, or tingling at the edge of active lesions in the days before visible enlargement., Slow, unpredictable progression with alternating stable and active phases; some patients have decades-long quiescence after initial flare while others progress steadily..
01Sharply demarcated, milk-white or chalk-white macules and patches with a clear border separating depigmented from normally pigmented skin — most often on the hands, face, around the mouth and eyes, elbows, knees, and over bony prominences.
02Symmetric distribution in non-segmental disease, with new patches commonly appearing at sites of friction, pressure, or skin injury — the Koebner phenomenon — typically 10-14 days after trauma in roughly 20-30% of patients.
03
§ 03
How it’s diagnosed
diagnosis
Vitiligo is a clinical diagnosis confirmed by a trained dermatologist on examination. The hallmark is a sharply demarcated, depigmented (not merely hypopigmented) macule or patch with normal skin texture and no scale. Wood's lamp examination — long-wave ultraviolet light in a dark room — is the single most useful bedside tool: depigmented vitiligo skin emits a bright bluish-white fluorescence due to loss of epidermal melanin, while hypopigmented mimics such as pityriasis alba, post-inflammatory hypopigmentation, and nevus depigmentosus appear less striking. Wood's lamp also reveals subclinical patches and helps map disease extent for treatment planning. The 2012 Vitiligo Global Issues Consensus distinguishes non-segmental from segmental disease — a distinction that drives prognosis and therapy. Disease activity is graded clinically (Vitiligo Disease Activity score, VIDA) and by signs of activity such as trichrome borders, confetti-like depigmentation, hypochromic edges, and Koebner phenomenon. Total body surface area is quantified using the Vitiligo Extent Score (VES) or the Vitiligo Area Scoring Index (VASI). Skin biopsy is reserved for atypical presentations — typically to distinguish vitiligo from mycosis fungoides hypopigmented variant, lichen sclerosus, or leprosy. Histology shows absence of melanocytes and melanin in lesional skin with preserved skin architecture, sometimes with a sparse perilesional lymphocytic infiltrate in active disease. Because vitiligo clusters with other autoimmune diseases, every newly diagnosed adult patient should be screened for thyroid autoimmunity (TSH and anti-thyroid peroxidase antibodies); additional screening for vitamin B12 and fasting glucose is appropriate based on symptoms or family history. Children with vitiligo should be screened annually for thyroid disease through adolescence.
Key tests
01
Wood's lamp examinationLong-wave UVA in a dark room highlights depigmented vitiligo patches as bright bluish-white fluorescence and distinguishes true vitiligo from hypopigmented mimics such as pityriasis alba, post-inflammatory hypopigmentation, and tinea versicolor.
✓Narrowband UVB phototherapy (311-313 nm), 2-3 sessions per week for 6-12 months
✓308 nm excimer laser, 2 sessions per week for 12-24 weeks
✓Topical corticosteroids (clobetasol 0.05% or mometasone 0.1% once daily)
surgical options
Punch graftingAcceptable repigmentation in 70-80% of segmental patches; lower in non-segmental disease. Cobblestone appearance is the main cosmetic limitation.
Suction blister epidermal grafting≥75% repigmentation in 70-85% of stable segmental cases; outcomes more variable in non-segmental disease.
Non-cultured epidermal cell suspension (Jodhpur technique / NCES)≥75% repigmentation in 70-90% of stable segmental patches; reduced but still meaningful response in stable non-segmental disease (Mulekar 2008).
Cultured melanocyte transplantation≥75% repigmentation in 60-80% of stable cases in case series; cost and laboratory availability limit routine use.
§ 05
Causes & risk factors
known causes
Autoimmune destruction of melanocytes by CD8+ T cells
The central mechanism. Autoreactive CD8+ T cells recognize melanocyte-specific antigens such as tyrosinase, MART-1, gp100, and TRP-1, and lyse the cells directly. IFN-γ signalling and the CXCL9/CXCL10 chemokine axis amplify recruitment of effector cells, which is why JAK inhibitors that block IFN-γ signalling work clinically.
Genetic susceptibility
Concordance is roughly 23% in monozygotic twins, indicating a strong but incomplete genetic component. Genome-wide studies identify over 50 risk loci, dominated by HLA class I/II, NLRP1, PTPN22, TYR, and IFIH1 — many shared with other autoimmune diseases.
Oxidative stress within melanocytes
Affected melanocytes show elevated hydrogen peroxide, defective catalase activity, and increased mitochondrial reactive oxygen species. This intrinsic oxidative stress generates neoantigens that prime the autoimmune attack — the convergence theory of vitiligo.
Skin trauma, friction, and chemical exposure (Koebner phenomenon)
Mechanical injury, friction at belt and bra lines, sunburn, and exposure to phenolic compounds (rubber, certain hair dyes, monobenzone) can precipitate or worsen vitiligo at the affected site in 20-30% of patients.
Emotional and physiological stress
Acute stressful life events precede the onset or worsening of vitiligo in roughly 60% of self-reported series. Stress-induced changes in catecholamines and neuropeptides may shift the cutaneous immune milieu toward autoimmunity.
Pregnancy and hormonal shifts
Some women report onset or progression around pregnancy or menopause, though the evidence remains observational. Postpartum hormonal and immune shifts are the most plausible mediators.
risk factors
§ 06
Living with it
01Apply daily broad-spectrum sunscreen SPF 30-50 to all sun-exposed depigmented and pigmented skin — prevents sunburn-driven Koebner spread and protects melanocyte-free patches from UV damage
02Avoid tight clothing, watch bands, and waistbands that produce repeated friction in active disease — Koebner phenomenon is responsible for many new patches
03Identify and stop occupational or cosmetic exposure to phenolic compounds (rubber, certain hair dyes, monobenzone) in patients with progressive disease
04Manage stress with structured methods (cognitive behavioural therapy, mindfulness-based stress reduction); psychological stress correlates with flares in 60% of self-reported series
05Screen first-degree relatives of vitiligo patients for autoimmune thyroid disease and type 1 diabetes if symptomatic — early detection of comorbidities improves quality of life
06Treat any new active patch within 6-12 months — earlier intervention yields greater repigmentation than waiting for stable disease
recommended foods
•Coloured fruits and vegetables high in antioxidants (berries, leafy greens, citrus, peppers) to support endogenous antioxidant defences
§ 07
When to seek help
why see an ophthalmology
See a dermatologist for any new depigmented patch that does not return after a few weeks, especially if it appears on the face, hands, or genitals, if patches are spreading rapidly, if eyelashes or eyebrows are turning white inside patches, or if first-line topical therapy fails after 3 months. Specialist referral is essential before starting phototherapy, oral mini-pulse steroids, or surgical interventions, and for children and adolescents where treatment choice and psychosocial support must be tailored together.
01Sunburn and chronic photodamage of melanocyte-free patches, raising long-term skin cancer risk on those sites — daily SPF protection is essential
02Psychiatric comorbidity — depression affects 25-35% of patients in published cohorts, anxiety up to 30%, and suicidal ideation is elevated in adolescents and patients with facial involvement
03Autoimmune thyroid disease (Hashimoto thyroiditis or Graves disease) in 15-20% of adult patients; annual TSH and anti-TPO screening is standard
04Other organ-specific autoimmune diseases — type 1 diabetes, Addison disease, pernicious anemia, alopecia areata — at modestly increased rates
05Ocular involvement (uveitis, iritis) and inner-ear melanocyte involvement in a small subset, occasionally part of the Vogt-Koyanagi-Harada spectrum
Non-segmental vitiligo — generalized (vitiligo vulgaris)The commonest subtype (~70-80% of all cases). Bilateral, symmetric patches scattered over the body; chronic course with active and stable phases. Strongly autoimmune-mediated.
Non-segmental vitiligo — acrofacialLimited to the face, lips, fingertips, and toes; often the first presentation of generalized disease. Responds less well to phototherapy than truncal sites.
Non-segmental vitiligo — universalDepigmentation of more than 80% of body surface area. Often the endpoint of long-standing untreated generalized disease; treatment shifts toward complete depigmentation with monobenzone.
Segmental vitiligoUnilateral patches following a band-like or quasi-dermatomal pattern, often on the face along the trigeminal distribution. Onset usually in childhood, rapid progression for 1-2 years, then long-term stability. Less autoimmune comorbidity; better surgical candidates.
Mixed vitiligoSegmental disease that later develops bilateral non-segmental patches. Treated according to the dominant pattern at presentation.
Focal vitiligoOne or a few isolated patches without obvious segmental or generalized distribution. Considered unclassified until the pattern declares itself over 1-2 years of follow-up.
Living with Vitiligo of left upper eyelid and periocular area
Timeline
First signs of repigmentation typically appear after 8-12 weeks of consistent therapy as small dotted islands of pigment around hair follicles within a depigmented patch. Visible patch shrinkage develops over 3-6 months with topical therapy and 4-8 months with phototherapy combined with topical agents. Maximum response is usually reached at 12-18 months, after which further gains are slow. Surgical repigmentation after non-cultured epidermal cell suspension or punch grafting becomes visible at 6-12 weeks post-procedure and matures over 6-12 months. Maintenance therapy with twice-weekly topical tacrolimus reduces 12-month relapse rates from roughly 40% to under 10% (Cavalié 2015 J Invest Dermatol).
Lifestyle
01Wear sun-protective clothing (UPF 50 fabrics, wide-brimmed hats) over exposed depigmented areas during peak UV hours
02Adopt an anti-inflammatory dietary pattern (Mediterranean or DASH-style) rich in coloured vegetables, fruits, whole grains, and oily fish to support antioxidant defences
03Use camouflage cosmetics and dihydroxyacetone-based self-tanners on visible patches if cosmetic distress is high while medical therapy continues
04Avoid skin trauma where possible — refrain from aggressive scrubs, harsh exfoliants, and unnecessary cosmetic procedures during active disease
05Build awareness within the family that vitiligo is not contagious and not caused by hygiene or diet, to reduce stigma at home and school
06Engage with a patient organization (Global Vitiligo Foundation, Vitiligo Society UK, VR Foundation) for community support and access to current treatment information
Complementary approaches
Antioxidant supplementation (alpha-lipoic acid, vitamin C, vitamin E, coenzyme Q10) alongside NB-UVBSmall randomized trials (Dell'Anna 2007) show that a balanced antioxidant cocktail combined with NB-UVB improves repigmentation modestly versus phototherapy alone, likely by reducing intracellular oxidative stress in residual melanocytes.
Vitamin D supplementation if deficient (target 25-OH-D ≥30 ng/mL)Vitamin D deficiency is over-represented in vitiligo cohorts. Correction does not by itself induce repigmentation, but adequate vitamin D supports overall immune regulation and is reasonable adjunctive care.
Camouflage cosmetics (Dermablend, Vitiligo Cover, semi-permanent micropigmentation)Not a biological treatment but a critical psychosocial intervention. High-coverage cosmetic products and trained micropigmentation can dramatically reduce visibility and improve quality of life while medical therapy continues.
Choosing a doctor
Choose a board-certified dermatologist with experience in vitiligo and access to narrowband UVB phototherapy in their clinic or a partnering centre. For surgical treatment, look for centres offering non-cultured epidermal cell suspension or suction blister grafting and willing to share photographic outcomes. Dedicated vitiligo clinics in academic medical centres or national reference networks (Global Vitiligo Foundation centres in the US, BAD-affiliated centres in the UK) offer the highest integration of medical, surgical, phototherapy, and psychological care.
Patient support resources
Global Vitiligo Foundation →International clinician-led organization with patient education, treatment standards, and a directory of vitiligo specialists.
Vitiligo Society (UK) →UK-based patient charity with information leaflets, peer-support networks, and advocacy resources.
No. Vitiligo is an autoimmune disease in which the body's own immune system destroys melanocytes. It cannot be passed by skin contact, sharing clothes, sharing food, swimming pools, or any other means. Family clustering reflects shared genetic risk for autoimmunity, not transmission.
What causes vitiligo?▾▴
Vitiligo is caused by CD8+ T cells attacking and destroying epidermal melanocytes through interferon-gamma signalling. Genetic susceptibility (over 50 risk loci, including HLA, NLRP1, and PTPN22), oxidative stress within melanocytes, skin trauma (the Koebner phenomenon), and major psychological stress all contribute to triggering and progression in susceptible individuals.
Is vitiligo curable?▾▴
Vitiligo is not curable in the sense that the underlying autoimmune tendency persists, but it is increasingly treatable. Topical ruxolitinib, narrowband UVB, topical corticosteroids and calcineurin inhibitors, and surgical techniques restore meaningful pigment in the majority of motivated patients with non-segmental disease. Maintenance therapy reduces relapse rates from around 40-50% to under 10% at one year.
How is vitiligo diagnosed?▾▴
Vitiligo is a clinical diagnosis made by a dermatologist on examination. The hallmark is sharply demarcated milk-white patches that fluoresce bright bluish-white under a Wood's lamp in a dark room. Atypical cases are confirmed by skin biopsy showing absence of melanocytes. Blood tests for thyroid antibodies and vitamin B12 are routinely added because of autoimmune comorbidity.
What is the difference between segmental and non-segmental vitiligo?▾▴
Non-segmental vitiligo is bilateral, symmetric, and chronic with active and stable phases; it accounts for 70-80% of cases and is strongly autoimmune-mediated. Segmental vitiligo is unilateral, follows a band-like distribution, usually starts in childhood, progresses rapidly for 1-2 years and then stabilizes. Segmental disease responds best to surgical treatment.
How well does ruxolitinib cream work for vitiligo?▾▴
In the phase 3 TRuE-V1 and TRuE-V2 trials, topical ruxolitinib 1.5% cream achieved at least 50% facial repigmentation in roughly 30% of patients at 24 weeks and in 50% by 52 weeks. Total-body 50% repigmentation was reached by about 20% at 24 weeks. The cream is approved for non-segmental vitiligo from age 12 with up to 10% body surface coverage.
What is narrowband UVB phototherapy?▾▴
Narrowband UVB delivers a narrow band of ultraviolet B light at 311-313 nm in a dermatology clinic phototherapy unit, two to three times a week for 6-12 months. It suppresses cutaneous T cells and stimulates melanocyte migration from hair follicles into depigmented skin. It achieves at least 25% repigmentation in 60-75% of patients with non-segmental disease.
Can vitiligo be cured by diet?▾▴
No diet cures vitiligo. There is no evidence that any specific food causes or eliminates the disease. A balanced anti-inflammatory dietary pattern rich in coloured vegetables, fruits, and oily fish supports general health and antioxidant defences, but it does not replace topical therapy, phototherapy, or surgical treatment.
Is vitiligo linked to thyroid disease?▾▴
Yes. Autoimmune thyroid disease, especially Hashimoto thyroiditis, affects 15-20% of adults with vitiligo compared with around 5% in the general adult population. Annual TSH plus anti-TPO antibody screening is standard care, with more frequent testing in children and any patient with new fatigue, weight change, or temperature intolerance.
Does vitiligo run in families?▾▴
Yes, to a degree. About 20-25% of patients have an affected first-degree relative. Twin studies show roughly 23% concordance in identical twins, indicating a strong but incomplete genetic component. Risk is polygenic rather than simple Mendelian, and lifetime environmental triggers (stress, trauma, chemicals) determine if and when the disease declares itself.
Can children get vitiligo?▾▴
Yes. Roughly half of all vitiligo cases begin before age 20 and about 25% before age 10. Childhood vitiligo includes a higher proportion of segmental disease and carries a substantial psychosocial burden. Topical tacrolimus or pimecrolimus, narrowband UVB, and 308 nm excimer laser are well-established treatments in paediatric dermatology.
Does sunlight help or hurt vitiligo?▾▴
Both. Controlled medical UVB exposure in a phototherapy unit stimulates repigmentation and is a cornerstone of treatment. Uncontrolled outdoor sun causes sunburn and Koebner spread on melanocyte-free patches and increases long-term skin cancer risk. Daily broad-spectrum sunscreen SPF 30-50 on uncovered skin is essential for every vitiligo patient.
Can stress trigger vitiligo?▾▴
Major psychological stress precedes onset or worsening of vitiligo in roughly 60% of patient series. Stress is not the only cause, but in genetically susceptible people it can shift cutaneous immunity toward autoimmune attack. Structured stress management, cognitive behavioural therapy, or mindfulness-based approaches measurably improve overall outcomes.
Why are my eyelashes or eyebrows turning white?▾▴
Loss of pigment in eyelashes, eyebrows, or scalp hair within a vitiligo patch is called leukotrichia. It reflects destruction of follicular melanocytes, which act as the reservoir for repigmentation. Leukotrichia at a site predicts a poorer repigmentation response there because the reservoir is depleted; surgical techniques may be needed for cosmetic restoration.
Can vitiligo spread to the whole body?▾▴
Generalized non-segmental vitiligo can progress over years and in a minority of patients reaches the universal stage with more than 80% body involvement. Rapid spread is more common during active phases with confetti-like depigmentation and Koebner phenomenon. Early treatment during active phases substantially reduces the chance of extensive progression.
How long does treatment take to show results?▾▴
First signs of repigmentation typically appear after 8-12 weeks of consistent therapy as small dotted islands of pigment around hair follicles within a patch. Visible shrinkage of patches develops over 3-6 months with topical therapy and 4-8 months with phototherapy. Maximum response is usually reached at 12-18 months of continuous treatment.
Will the white patches come back after treatment stops?▾▴
Relapse occurs in roughly 40-50% of patients within 12 months of stopping active therapy. Proactive maintenance therapy with topical tacrolimus 0.1% ointment applied twice weekly to previously affected sites reduces 12-month relapse rates to under 10% in randomized data (Cavalié 2015). Sun protection, stress management, and ongoing dermatology follow-up are essential.
Is there a vaccine or pill for vitiligo?▾▴
There is no vaccine. Approved pharmacotherapy for non-segmental vitiligo currently includes topical ruxolitinib 1.5% cream (FDA-approved 2022). Oral JAK inhibitors and other systemic therapies are in active phase 3 trials and may become available in the next several years. Oral mini-pulse corticosteroids are used off-label for rapidly progressing disease.
Does vitiligo affect life expectancy?▾▴
Vitiligo itself does not shorten life expectancy. It can affect quality of life substantially, and associated autoimmune diseases such as thyroid disorders and type 1 diabetes have their own implications. Regular screening for autoimmune comorbidity, sun protection on melanocyte-free skin, and mental health support are part of standard long-term care.
Can I get a tattoo if I have vitiligo?▾▴
Tattooing carries a real risk of triggering new vitiligo patches at the tattoo site through the Koebner phenomenon, particularly in active disease. Medical micropigmentation by a trained practitioner can camouflage stable patches but is not first-line and should be discussed with a dermatologist after disease has been stable for at least 12 months.
Is vitiligo skin cancer?▾▴
No. Vitiligo is an autoimmune disease, not a cancer. Paradoxically, large cohort studies suggest a slightly lower overall risk of melanoma and non-melanoma skin cancer in vitiligo patients, possibly reflecting overlapping immune surveillance. Sun protection of depigmented skin remains essential because individual patches lack melanin defence against UV damage.
When should I see a specialist for vitiligo?▾▴
See a dermatologist for any new depigmented patch that does not resolve within a few weeks, especially on the face, hands, or genitals, or if patches are spreading rapidly, if eyelashes or eyebrows are turning white inside patches, or if first-line topical therapy fails after 3 months. Specialist input is essential before starting phototherapy, oral steroids, or surgery.
Premature greying or whitening of scalp hair, eyebrows, eyelashes, or beard (leukotrichia) within affected patches, indicating loss of follicular melanocytes and a poorer repigmentation prognosis at that site.
04Trichrome appearance at the edge of expanding patches, with a pale intermediate zone between fully depigmented centre and normally pigmented surrounding skin — a sign of active disease.
05Confetti-like depigmentation — small 1-5 mm white macules at the periphery of larger patches — a clinical marker of rapidly progressive vitiligo.
06Patches are typically asymptomatic, but a minority of patients report mild itching, burning, or tingling at the edge of active lesions in the days before visible enlargement.
07Slow, unpredictable progression with alternating stable and active phases; some patients have decades-long quiescence after initial flare while others progress steadily.
08Greater visual contrast and psychological distress in darker (Fitzpatrick IV-VI) skin types, even when total body surface area involved is small.
09Sun-exposed patches sunburn easily and never tan — unprotected exposure produces erythema and blistering rather than pigment.
10Mucosal depigmentation of the lips, gums, and genitals, particularly in long-standing generalized disease.
early warning signs
•A single small chalk-white macule on the hand, face, or eyelid that fails to tan with sun exposure over several weeks
•Premature greying of scalp hairs or eyelashes localized to one area, especially before age 25
•Repeated appearance of white patches at sites of scratches, burns, friction, or surgical scars within 2-3 weeks of injury (Koebner phenomenon)
•A family history of vitiligo, autoimmune thyroid disease, type 1 diabetes, alopecia areata, or pernicious anemia in a first-degree relative
•Iritis or uveitis without obvious cause — melanocyte autoimmunity can extend to the eye and inner ear
● emergency signs
•Rapidly enlarging patches with confetti-like satellite macules and trichrome borders over weeks — active vitiligo that benefits from urgent systemic corticosteroid mini-pulse therapy before further melanocyte loss
•Severe symptoms of hypothyroidism (cold intolerance, fatigue, weight gain, bradycardia) or hyperthyroidism in a patient with vitiligo — refer for endocrine evaluation rather than wait for routine screening
•Onset of vitiligo with concurrent fatigue, salt craving, postural dizziness, and hyperpigmentation of unaffected skin — exclude autoimmune Addisonian crisis, which can coexist
•Sudden vision changes, eye pain, or hearing loss in a vitiligo patient — possible Vogt-Koyanagi-Harada-spectrum involvement of ocular and inner-ear melanocytes; urgent ophthalmology and ENT evaluation
•Suicidal ideation, severe depression, or social withdrawal in any patient with visible vitiligo — psychosocial burden is high, especially in darker skin types and adolescents
Clinical skin examination with VIDA and VES/VASI scoringConfirms the diagnosis on morphology and distribution, classifies non-segmental versus segmental disease, and grades activity and extent for treatment planning.
03
Punch skin biopsy with histopathologyReserved for atypical presentations. Confirms absence of melanocytes with Melan-A or HMB-45 staining, and excludes mycosis fungoides hypopigmented variant, lichen sclerosus, and leprosy.
04
Thyroid function and antibody panel (TSH, free T4, anti-TPO)Screens for autoimmune thyroid disease, present in 15-20% of adult vitiligo patients. Anti-TPO positivity predicts later overt thyroid dysfunction even when TSH is normal.
05
Vitamin B12 and complete blood countScreens for pernicious anemia, which co-occurs with vitiligo more often than in the general population, and identifies B12 deficiency that can mimic neurological symptoms.
06
Fasting glucose and HbA1cScreens for type 1 diabetes in younger patients and type 2 diabetes in adults, both more prevalent in vitiligo populations.
07
Dermoscopy of patchesIdentifies signs of active disease (perifollicular pigmentation loss, trichrome appearance) and signs of repigmentation potential (intact hair follicles within patches).
Outlook
Vitiligo is a lifelong condition without a definitive cure, but treatment outcomes have improved markedly with the introduction of topical JAK inhibitors and refined phototherapy protocols. Roughly 60-75% of motivated patients with non-segmental disease achieve at least 25% repigmentation with narrowband UVB combined with a topical agent, and 30-50% achieve 50% or greater repigmentation over 6-12 months. Facial and truncal patches respond best; hands, feet, lips, and bony prominences respond least. Segmental disease tends to stabilize within 1-2 years of onset and responds best to surgical techniques, with 75-90% repigmentation rates in selected patients. Relapse after stopping therapy occurs in 40-50% within 12 months unless maintenance topical tacrolimus or proactive twice-weekly therapy is used. Vitiligo does not affect life expectancy directly, but the psychological burden — depression rates of 25-35% in published cohorts, especially in darker skin types and adolescents — measurably affects quality of life and is now considered a core treatment target. Early intervention during active disease, before extensive follicular melanocyte loss occurs, predicts the best long-term outcomes.
Family history of vitiligogenetic
Roughly 20-25% of patients have an affected first-degree relative. Heritability is substantial but inheritance is polygenic, not Mendelian.
Personal or family history of organ-specific autoimmunitygenetic
Autoimmune thyroid disease, type 1 diabetes, pernicious anemia, alopecia areata, Addison disease, and rheumatoid arthritis cluster in vitiligo patients and their families.
Age under 20 at onsetnon-modifiable
Half of all cases begin before age 20. Childhood-onset vitiligo carries higher risk of segmental subtype and greater psychosocial burden but similar long-term repigmentation potential with treatment.
Repeated skin trauma or frictionmodifiable
Belt lines, bra straps, watch bands, surgical scars, and tight clothing predict Koebner-driven new patches in active disease. Avoiding tight clothing and protecting skin during active phases reduces new lesion formation.
Chronic sun damage and severe sunburnenvironmental
Sunburn is a documented Koebner trigger, and unprotected exposure damages residual melanocytes in active patches. Daily SPF 30+ on uncovered skin is part of standard management.
Occupational or cosmetic exposure to phenolic and catechol compoundsenvironmental
Para-tertiary butylphenol (rubber, adhesives), monobenzone, hydroquinone, and certain hair dyes are documented chemical inducers of vitiligo-like depigmentation in susceptible individuals.
Major psychosocial stressmodifiable
Bereavement, divorce, job loss, and severe academic or occupational stress are reported as flare triggers in roughly 60% of patient series, though causality remains observational.
Female sex (clinical-presentation bias)non-modifiable
Incidence is similar across sexes, but women present earlier and more often, likely reflecting cosmetic concern. Treatment outcomes are similar between sexes.
•Oily fish 2-3 times per week (salmon, sardines, mackerel) for omega-3 fatty acids
•Whole grains, legumes, and nuts as sources of B vitamins and minerals (zinc, copper) needed for melanin synthesis
•Adequate vitamin D from sunlight (with sunscreen on patches) or oral supplementation if deficient
•Plenty of water — 2 litres daily unless restricted for other reasons
foods to avoid
•Restrictive elimination diets and crash dieting — there is no evidence any food causes vitiligo, and severe restriction adds nutritional risk without benefit
•Excess alcohol, which can interact with mini-pulse steroids and antioxidants and compounds psychological distress
•Ultra-processed foods and high added-sugar intake that drive systemic inflammation
•Unproven herbal cocktails marketed online as vitiligo cures — many contain undisclosed steroids or heavy metals
•Unsupervised high-dose copper or vitamin supplements promoted on social media — copper toxicity is a real risk
06Side effects of long-term unsupervised potent topical steroid use — skin atrophy, telangiectasia, and rarely systemic absorption in children
07Disease relapse after stopping maintenance therapy in roughly 40-50% within 12 months unless proactive twice-weekly tacrolimus is used
choosing the right hospital
01Phototherapy unit equipped with narrowband UVB and ideally 308 nm excimer laser
03On-site dermatopathology for atypical depigmentation cases
04Endocrinology partnership for thyroid and other autoimmune screening
05Clinical psychology or counselling integration for adult and paediatric patients
Leukoderma is acquired loss of pigment after specific causes — burns, severe inflammation, infection, or chemical exposure (phenols, monobenzone). The pattern is restricted to the site of insult and lacks the symmetric or segmental distribution of vitiligo, though chemical leukoderma can later trigger true vitiligo in susceptible individuals.
05Keep a brief diary of new patches, sites of friction or injury, and stressful events for the first 6 months
06Discuss any new symptoms (fatigue, cold intolerance, weight change, palpitations) with your dermatologist — they may indicate emerging autoimmune comorbidity
Exercise
Aim for 150 minutes of moderate aerobic activity per week plus two resistance sessions, the standard adult target. Exercise reduces stress and improves overall immune regulation. Apply sunscreen on exposed patches before outdoor activity, wear UPF clothing on prolonged sun exposure, and shower promptly afterward to reduce friction-related Koebner spread from tight workout clothes. Public-pool chlorine is generally tolerated, but rinse thoroughly afterward.